Kissei Pharmaceutical, Daiichi Pharmaceutical Jointly Launch Urination Disorder Improving Drug.Tokyo, Japan, May 11, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - On May 10, Kissei Pharmaceutical and Daiichi Pharmaceutical jointly announced that they will launch URIEF Cap. 2mg/ 4mg (silodosin), an agent for treating urination urination Process of excreting urine from the bladder (see urinary system). Nerve centres in the spinal cord, brain stem, and cerebral cortex control it through involuntary and voluntary muscles. The need to void is felt when the bladder holds 3. disorder associated with benign prostatic hypertrophy Benign prostatic hypertrophy (BPH) Benign prostatic hypertrophy is an enlargement of the prostate that is not cancerous. However, it may cause problems with urinating or other symptoms. (BPH BPH abbr. benign prostatic hyperplasia BPH Benign prostatic hypertrophy, a very common noncancerous cause of prostatic enlargement in older men. ), on May 11. The new agent, a selective alpha-1A receptor blocker developed by Kissei Pharmaceutical, helps improve urethral resistance and alleviate urination disorder. The agent is scheduled to be available later in the US, Canada, Mexico, Europe, Middle Eastern countries, China, and Korea. Kissei Pharmaceutical aims to generate 40 billion yen ($354.0 mil) in domestic sales and 100 billion yen ($885.0 mil) in global sales in peak times. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion